Filing Details

Accession Number:
0000950170-25-021346
Form Type:
13G Filing
Publication Date:
2025-02-13 19:00:00
Filed By:
TCG Crossover GP I, LLC
Company:
An2 Therapeutics Inc.
Filing Date:
2025-02-14
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
TCG Crossover GP I, LLC 0 0 0%
TCG Crossover Fund I, L.P. 0 0 0%
Chen Yu 0 0 0%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G


 
TCG Crossover GP I, LLC
 
Signature:/s/ Craig Skaling
Name/Title:Craig Skaling, Authorized Signatory
Date:02/14/2025
 
TCG Crossover Fund I, L.P.
 
Signature:/s/ Craig Skaling
Name/Title:Craig Skaling, Authorized Signatory
Date:02/14/2025
 
Chen Yu
 
Signature:/s/ Craig Skaling
Name/Title:Craig Skaling, as attorney-in-fact for Chen Yu
Date:02/14/2025